Novavax, Inc. (Nasdaq: NVAX) announced that the enrollment of over 3,500 subjects in Mexico has been completed in Stage B of its pivotal 2009 H1N1 virus-like-particle ( VLP) pandemic influenza vaccine study….
The rest is here:
NOVAVAX Completes Enrollment Of Pivotal H1N1 Influenza Vaccine Clinical Trial In Mexico
Novavax, Inc. (Nasdaq: NVAX) announced that the enrollment of over 3500 subjects in Mexico has been completed in Stage B of its pivotal 2009 H1N1 virus -like-particle (VLP) pandemic influenza vaccine study. With the 1000 subjects already …
Link:
NOVAVAX Completes Enrollment Of Pivotal H1N1 Influenza Vaccine …
… n Stage B of its pivotal 2009 H1N1 virus-like-particle (VLP) pandemic influenza vaccine study. With the 1,000 subjects already…
Read the rest here:
Clinical Trials & Medical Discoveries
Novavax, Inc. announced today that the enrollment of over 3,500 subjects in Mexico has been completed in Stage B of its pivotal 2009 H1N1 virus-like-particle (VLP) pandemic influenza vaccine study. With the 1,000 subjects already enrolled in Stage A of the trial, the enrollment in this pivotal trial is now complete with over 4,500 subjects.
See the rest here:
NOVAVAX’ Stage B 2009 H1N1 VLP pandemic influenza vaccine study in Mexico: Enrollment complete (News-Medical-Net)
Novavax, Inc. announced today that the enrollment of over 3500 subjects in Mexico has been completed in Stage B of its pivotal 2009 H1N1 virus -like-particle (VLP) pandemic influenza vaccine study. With the 1000 subjects already enrolled …
The rest is here:
NOVAVAX' Stage B 2009 H1N1 VLP pandemic influenza vaccine study in …
Positive Clinical Results from Pivotal Study of H1N1 Virus -Like Particle (VLP) Pandemic Influenza Vaccine in Mexico – Immunogenicity responses at all dose lev.
Read the original post:
NOVAVAX Presents Positive Clinical Results at The World Health …
Novavax, Inc. announced today new data from a clinical study that began in May of 2009 among healthy adults 18 to 49 years of age with Novavax’s trivalent seasonal influenza Virus-like Particle (VLP) vaccine. The vaccine matched the influenza strains recommended for the 2008-2009 influenza season including H1N1 A/Brisbane/59/2007, H3N2 A/Brisbane/10/2007, and B/Florida/04/2006 strains.
More:
Novavax announces new data from trivalent seasonal influenza VLP vaccine study (News-Medical-Net)
Novavax, Inc. (Nasdaq: NVAX ) announced today new data from a clinical study that began in May of 2009 among healthy adults 18 to 49 years of age with Novavax’s trivalent seasonal influenza Virus-like Particle (VLP) vaccine.
Novavax, Inc. (Nasdaq: NVAX ) announced today new data from a clinical study that began in May of 2009 among healthy adults 18 to 49 years of age with Novavax’s trivalent seasonal influenza Virus-like Particle (VLP) vaccine.
Read the original:
NOVAVAX Reports Additional Positive Data From Its Trivalent Seasonal Influenza (VLP) Vaccine Clinical Study In Healthy … (PharmaceuticalOnline)
ROCKVILLE, Md., Feb. 8 /PRNewswire-FirstCall/ — Novavax, Inc. (Nasdaq: NVAX) announced today new data from a clinical study that began in May of 2009 among healthy adults 18 to 49 years of age with Novavax’s trivalent seasonal influenza Virus-like Particle (VLP) vaccine.
Read the original:
NOVAVAX Reports Additional Positive Data from Its Trivalent Seasonal Influenza (VLP) Vaccine Clinical Study in Healthy … (redOrbit)